A61K - Preparations for medical, dental, or toilet purposes

More topics under "A61K - Preparations for medical, dental, or toilet purposes" (2,585,043)
A61K 101 - Radioactive non-metals (526)
A61K 103 - Radioactive metals (481)
A61K 125 - Containing or obtained from roots, bulbs, tubers, corms or rhizomes (2,645)
A61K 127 - Containing or obtained from leaves (1,806)
A61K 129 - Containing or obtained from bark (325)
A61K 131 - Containing or obtained from seeds, nuts, fruits or grains (1,932)
A61K 133 - Containing or obtained from flowers or blossoms (665)
A61K 135 - Containing or obtained from stems, stalks, branches, twigs or shoots (756)
A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
A61K 33 - Medicinal preparations containing inorganic active ingredients (56,213)
A61K 35 - Medicinal preparations containing material or reaction products thereof with undetermined constitution (125,838)
A61K 36 - Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines (179,316)
A61K 38 - Medicinal preparations containing peptides (316,240)
A61K 39 - Medicinal preparations containing antigens or antibodies (182,248)
A61K 41 - Medicinal preparations obtained by treating materials with wave energy or particle radiation (9,445)
A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020)
A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128)
A61K 48 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy (86,964)
A61K 49 - Preparations for testing in vivo (35,376)
A61K 50 - Electrically conductive preparations for use in therapy or testing in vivo, e.g. conductive adhesives or gels to be used with electrodes for electrocardiography (ecg) or for transcutaneous drug administration (62)
A61K 51 - Preparations containing radioactive substances for use in therapy or testing in vivo (24,291)
A61K 6 - Preparations for dentistry (18,259)
A61K 8 - Cosmetics or similar toilet preparations (170,551)
A61K 9 - Medicinal preparations characterised by special physical form (299,044)

Patents for A61K - Preparations for medical, dental, or toilet purposes (29,449)
12/2004
12/16/2004	CA2528136A1 Transfection agents
12/16/2004	CA2527693A1 Polymorphic forms of naltrexone
12/16/2004	CA2527658A1 Methods and compositions for interferon therapy
12/16/2004	CA2527211A1 Anti-hiv benzamide compounds
12/16/2004	CA2527114A1 Methods for the protection of memory and cognition
12/16/2004	CA2526007A1 Releasable polymeric conjugates based on aliphatic biodegradable linkers
12/16/2004	CA2525752A1 Cannabinoid receptor ligands and uses thereof
12/16/2004	CA2521682A1 Delivery of immune response modifier compounds using metal-containing particulate support materials
12/15/2004	EP1485393A2 9-dexo-9a-aza-9a-methyl-9a-homoerythromycin a derivatives
12/15/2004	EP1485127A2 Administration of agents for the treatment of inflammation
12/15/2004	EP1485114A2 Isolation, purification and structural identification of a bioactive component of a water soluble extract of a botanical species for enhancing immune, anti-inflammatory, anti-tumor and dna repair processes of warm blooded animals
12/15/2004	EP1485056A2 Methods of using fet labeled oligonucleotides that include a'5' exonuclease resistant quencher domain and compositions for practicing the same
12/15/2004	EP1226137B8 Phenyl- and pyridyl-tetrahydro-pyridines having tnf inhibiting activity
12/15/2004	EP1047415B1 Pig appeasing pheromones to decrease stress, anxiety and aggressiveness
12/15/2004	CN1555259A use of substituted aminomethyl chromans for the treatment of movement disorders and of adverse effects induced by drugs administered to treat extrapyramidal movement disorders
12/15/2004	CN1555254A 免疫原性脂质体组合物 Immunogenic liposome composition
12/15/2004	CN1179753C Contraceptive compositions containing antiprogesting and progestinic
12/14/2004	US6830765 Extract of green tea containing from 20% to 50% by mass of catechols expressed as epigallocatechol gallate
12/09/2004	WO2004105780A2 Compositions comprising gastrin compounds and their use in diabetes
12/09/2004	WO2004105704A2 Emulsion base for skin care compositions
12/09/2004	WO2004105701A2 Compositions and methods for symptomatic relief
12/09/2004	WO2004105700A2 Compounds, methods and pharmaceutical compositions for inhibiting parp
12/09/2004	WO2004105699A2 Compositions of a cyclooxygenase-2 selective inhibitor and a cannabinoid agent for the treatment of central nervous system damage
12/09/2004	WO2004105698A2 Use of phosphatase inhibitors as adjunct therapy for psychiatric disorders
12/09/2004	WO2004105697A2 Novel lipids for transfection of nucleic acids
12/09/2004	WO2004105696A2 Combination therapy for the treatment of neoplasms
12/09/2004	WO2004105695A2 Methods and materials for treating, detecting, and reducing the risk of developing alzheimer’s disease
12/09/2004	WO2004105694A2 Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs
12/09/2004	WO2004105693A2 Components, systems and methods for forming anastomoses using magnetism or other coupling means
12/09/2004	WO2004105692A2 Smooth muscle spasmolytic agents
12/09/2004	WO2004105690A2 Treatment of chronic pain associated with drug or radiation therapy
12/09/2004	WO2004105689A2 Topical composition for the treatment of skin disorders and methods of using the same
12/09/2004	WO2004105688A2 Bactericidal composition and associated method
12/09/2004	WO2004105687A2 Antimicrobial quaternary ammonium organosilane coatings
12/09/2004	WO2004105685A2 Displaceable linker solid phase chemical ligation
12/09/2004	WO2004105684A2 Combination therapy for proliferative disorders
12/09/2004	WO2004105682A2 Carbostyril derivatives and mood stabilizers for treating mood disorders
12/09/2004	WO2004105681A2 Cd4+ human papillomavirus (hpv) epitopes
12/09/2004	WO2004105680A2 Oral care products comprising calcium metasilicates
12/09/2004	WO2004105679A2 Use of a nutritional composition for treating hypertension
12/09/2004	WO2004105678A2 Pharmaceutical composition based on ketorolac or one of its salts pharmaceutically acceptable and use of ketorolac or its salts in pharmaceutical compositions
12/09/2004	WO2004091522A3 Method for treating neurodegenerative disorders
12/09/2004	WO2004091505A3 Bacteriophage for lysis of methylobacterium and compositions and uses thereof
12/09/2004	WO2004082591A8 Pharmaceutical composition for treatment of diabetes mellitus
12/09/2004	WO2004082564A3 Coated enzyme granules
12/09/2004	WO2004080408A3 Method of treating cancer with azaspirane compositions
12/09/2004	WO2004080389A3 Hydroxyeicosadienamide compounds
12/09/2004	WO2004078144A3 Diphenylethylene compounds and uses thereof
12/09/2004	WO2004075863A3 Cxcr3 antagonists
12/09/2004	WO2004071440A3 Thiazolyl-based compounds useful as kinase inhibitors
12/09/2004	WO2004071413A3 Method and composition for potentiating an opiate analgesic
12/09/2004	WO2004069194A9 Use of the oxidoreductase ncb50r for diagnosings and treating diabetes
12/09/2004	WO2004066961A3 Use of sendai virus as a human parainfluenza vaccine
12/09/2004	WO2004062628A3 Gilsonite derived pharmaceutical delivery compositions and methods
12/09/2004	WO2004062618A3 Method for in vivo regulation of cardiac muscle contractility
12/09/2004	WO2004062593A3 Antineoplastic ether lipid compounds with modifications at the sn-2 carbon
12/09/2004	WO2004062586A3 Antineoplastic ether lipid compounds
12/09/2004	WO2004062573A3 Oral-care device and system
12/09/2004	WO2004061084A8 Modulation of protein functionalities
12/09/2004	WO2004060310A3 Human growth hormone crystals and methods for preparing them
12/09/2004	WO2004060262A3 Modulators of notch signalling for use in immunotherpapy
12/09/2004	WO2004058183A3 Lymphotoxin beta receptor agents in combination with chemotherapeutic agents
12/09/2004	WO2004050848A3 Methods for antigen masking of red blood cells resulting in reduced hemolysis
12/09/2004	WO2004047736A3 Modulation of bcl2-associated athanogene expression
12/09/2004	WO2004043344A3 Anti-cd33 antibodies and method for treatment of acute myeloid leukemia using the same
12/09/2004	WO2004039319A3 Novel human polypeptides encoded by polynucleotides
12/09/2004	WO2004039314A3 Process for synthesizing l-y-methylene glutamic acid and analogs
12/09/2004	WO2004032863A3 Oral formulations for proteins and polypeptides
12/09/2004	WO2004032829A3 Immunostimulatory compositions and methods of stimulating an immune response
12/09/2004	WO2004028473A3 Synergistic compositions for the prevention and treatment of acquired immunodeficiency syndrome
12/09/2004	WO2004006866A3 Antifungal therapeutic targets
12/09/2004	US20040249426 Apparatus and method for the treatment of infectious disease in keratinized tissue
12/09/2004	US20040248987 N-alkyl-diphenyl-alkylene-amine derivatives; for the treatment of smooth muscle hyperactivity in urinary incontinence, gastrointestinal disorder, respiratory system disorder; promoting smooth muscle relaxation, reducing hypotension or cardiac side effects
12/09/2004	US20040248952 Novel bicyclic compounds and compositions
12/09/2004	US20040248942 Novel formulation, omeprazole antacid complex-immediate release for rapid and sustained suppression of gastric acid
12/09/2004	US20040248937 protein tyrosine phosphatase inhibitors such as N-[(4-{[4,6-bis(4-methoxyphenyl)pyrimidin-2-yl]amino}phenyl)sulfonyl]-N-methyl-L-phenylalanine, used for treatment of metabolic disorders related to insulin resistance or hyperglycemia
12/09/2004	US20040248936 such as (R)-1-{4-[4-(4-Phenoxy-2-propyl-phenoxy)-butoxy]-benzenesulfonyl}-azetidine-2-carboxylic acid, used as peroxisome proliferator-activated receptor agonists; hypoglycemic agents
12/09/2004	US20040248904 New piperidinylamino-thieno[2,3-d] pyrimidine compounds
12/09/2004	US20040248902 Central nervous system, gastrointestinal and psycological disorders; such as 3-(4-chlorobenzenesulfonyl)-2-methyl-7-piperazin-1-yl-1H-indole; synthesis
12/09/2004	US20040248887 Selective in presence of at least one other cathepsin isozyme; such as N-{-2-[2-(4-methoxy-phenylamino)-ethylcarbamoyl]-cyclohexyl}-3-methyl-benzamide
12/09/2004	US20040248881 such as 1-[2-(2-chloro-phenyl)-3-(4-fluoro-phenyl)-2H-pyrazolo[3,4-d]pyridazin-7-yl]-4-isopropylamino-piperidine-4-carboxylic acid amide; for treatment of eating disorders and psychological disorders
12/09/2004	US20040248853 Antiinflammatory agents; antihistamines; adult respiratory distress syndrome; antidiabetic agents; inflammatory bowel disorders
12/09/2004	US20040248850 Compounds for the treatment of HIV infection
12/09/2004	US20040248848 Use of specific dose of fondaparinux sodium for the treatment of acs
12/09/2004	US20040248839 RNAi targeting of viruses
12/09/2004	US20040248804 Nasal administration of the LH-RH analog Leuprolide
12/09/2004	US20040248800 Crystals and structures of epidermal growth factor receptor kinase domain
12/09/2004	US20040248798 Contraceptive methods and compositions related to proteasomal interference
12/09/2004	US20040248794 Treatment of dry eye by restoring 15-lipoxygenase activity to ocular surface cells
12/09/2004	US20040248262 Nucleotide sequences coding lysosomal protein for use treatment of brain and muscular disorders
12/09/2004	US20040248232 Method for treating Alzheimer's dementia
12/09/2004	US20040248212 determine the specific sequence of that portion of peptides or proteins that bind to a receptor or target of interest, or mediate a biological activity of interest; forming a metallopeptides with serially substituted sequences and screening for altered binding activity; metallopeptide libraries
12/09/2004	US20040247680 Targeted delivery of controlled release polymer systems
12/09/2004	US20040247623 Method and article for treatment of sensory neuron related disorders through transdermal application of botulinum toxin
12/09/2004	US20040247614 Lysine-acyetylated tat proteins of a human immunodeficiency virus; specifically binding antibodies; vaccination to inhibit transcriptional activation
12/09/2004	US20040247610 A lysine-glycine-lysine-glycine-Xaa pentapeptide residue complexed with one or more B-cell or T-cell determinants and targeting molecules; influenza type A vaccinations
12/09/2004	US20040247602 Treating a cancer, in particular breast cancer, that overexpresses Her-2 by administering an ADAM inhibitor; novel variants of ADAM15 and ADAM15; synergistic effect between inhibition of Her-2 cleavage by an ADAM and certain cytostatic (e.g., Herceptin) and cytotoxic (e.g., Taxol) compounds
12/09/2004	US20040247599 Modulators of the P2Y10 receptor useful in altering T lymphocyte function
12/09/2004	US20040247588 Lyophilizing a solution of a modified antibody (especially Certolizumab Pegol) containing molecules capable of adversely affecting the stability or solubility of the antibody after lyophilization and from which some of those moledules have been removed
12/09/2004	US20040247578 Administering into or near a site of a tumor or infectious lesion an antigen presenting cell, especially a dendritic cell, and an immunostimulatory cytokine or a nucleic acid encoding an immunostimulatory cytokine

1 ... 139 140 141 142 143 144 145 146 147 148 149 150 151 152 153 154 155 156 157 158 159 ... 295